Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 1: Current Role of Covalent Bruton Tyrosine Kinase Inhibitors and Bcl-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL) — Paolo Ghia, MD, PhD

CME information and select publications

Featuring perspectives from Ms Courtney Arn, Ms Jennifer Filipi, Dr David M O’Malley and Dr Shannon N Westin, including the following topics:

• Introduction: Overview of Ovarian Cancer (OC) Management (0:00)
• Genetic Testing for Newly Diagnosed Advanced OC (14:31)
• Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC (22:46)
• Other Available and Investigational Novel Strategies for OC (43:56)
• Current and Future Role of Mirvetuximab Soravtansine in OC Treatment (1:19:24)

NCPD information and select publications

Featuring perspectives from Dr Rahul Aggarwal and Dr William K Oh, including the following topics:

• Hormonal Therapy for Patients with Prostate Cancer — Dr Oh (0:00)
• Other Available and Emerging Therapeutic Approaches — Dr Aggarwal (27:14)

CME information and select publications

Featuring slide presentations and related discussion from Dr Hanny Al-Samkari, Dr James B Bussel and Prof Nichola Cooper, including the following topics:

• Introduction (0:00)
• Clinical Manifestations and Initial Management of Immune Thrombocytopenia (ITP) — Dr Al-Samkari (10:24)
• Second- and Later-Line Therapies for ITP — Dr Bussel (1:00:51)
• Tolerability and Other Practical Considerations with Available Treatment Strategies for Persistent/Chronic ITP — Prof Cooper (1:28:08)

CME information and select publications

Featuring perspectives from Dr Mitesh J Borad and Dr Amit Mahipal, including the following topics:

• Introduction (0:00)
• Targeted Therapeutic Approaches for Patients with Biliary Tract Cancers (BTCs) — Dr Mahipal (4:59)
• Integration of Immune Checkpoint Inhibitors into Current BTC Management — Dr Borad (32:16)

CME information and select publications

Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics:

• Introduction (0:00)
• Overview of Antibody-Drug Conjugates (ADCs) (4:40)
• Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases (12:40)
• Role of ADCs for Patients with ER-Positive mBC (35:09)
• T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations (52:20)
• Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC (1:12:20)

NCPD information and select publications

Featuring an interview with Dr Adam M Brufsky, including the following topics:

• Case: A woman in her early 50s with ER-positive, HER2-low de novo metastatic breast cancer (0:00)
• Case: A woman in her late 70s with ER-positive, HER2-low metastatic breast cancer after 5 years of an adjuvant aromatase inhibitor (6:52)
• Clinical Investigator Survey Results (10:05)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics:

• Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00)
• Comparing safety profiles of CDK4/6 inhibitors (9:49)
• Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06)
• Real-world evidence with CDK4/6 inhibitors (27:31)

CME information and select publications